Abstract
Alzheimers disease (AD) is an age-related neurodegenerative disease that affects approximately 24 million people worldwide. A number of different risk factors have been implicated in AD, however, neuritic (amyloid) plaques are considered as one of the defining risk factors and pathological hallmarks of the disease. Complement proteins are integral components of amyloid plaques and cerebral vascular amyloid in Alzheimer brains. They can be found at the earliest stages of amyloid deposition and their activation coincides with the clinical expression of Alzheimers dementia. This review emphasizes on the dual key roles of complement system and complement regulators (CRegs) in disease pathology and progression. The particular focus of this review is on currently evolving strategies for design of complement inhibitors that might aid therapy by restoring the fine balance between activated components of complement system, thus improving the cognitive performance of patients. This review discusses these issues with a view to inspiring the development of new agents that could be useful for the treatment of AD.
Keywords: Alzheimer's disease, neurodegeneration, inflammation, β-amyloid peptide, complement, complement regulators, CD59, complement therapeutics
Current Neuropharmacology
Title: Implication of Complement System and its Regulators in Alzheimers Disease
Volume: 7 Issue: 1
Author(s): Martin V. Kolev, Marieta M. Ruseva, Claire L. Harris, B. Paul Morgan and Rossen M. Donev
Affiliation:
Keywords: Alzheimer's disease, neurodegeneration, inflammation, β-amyloid peptide, complement, complement regulators, CD59, complement therapeutics
Abstract: Alzheimers disease (AD) is an age-related neurodegenerative disease that affects approximately 24 million people worldwide. A number of different risk factors have been implicated in AD, however, neuritic (amyloid) plaques are considered as one of the defining risk factors and pathological hallmarks of the disease. Complement proteins are integral components of amyloid plaques and cerebral vascular amyloid in Alzheimer brains. They can be found at the earliest stages of amyloid deposition and their activation coincides with the clinical expression of Alzheimers dementia. This review emphasizes on the dual key roles of complement system and complement regulators (CRegs) in disease pathology and progression. The particular focus of this review is on currently evolving strategies for design of complement inhibitors that might aid therapy by restoring the fine balance between activated components of complement system, thus improving the cognitive performance of patients. This review discusses these issues with a view to inspiring the development of new agents that could be useful for the treatment of AD.
Export Options
About this article
Cite this article as:
Kolev V. Martin, Ruseva M. Marieta, Harris L. Claire, Morgan Paul B. and Donev M. Rossen, Implication of Complement System and its Regulators in Alzheimers Disease, Current Neuropharmacology 2009; 7 (1) . https://dx.doi.org/10.2174/157015909787602805
DOI https://dx.doi.org/10.2174/157015909787602805 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting the Autophagy/Lysosomal Degradation Pathway in Parkinson´s Disease
Current Neuropharmacology Gender Differences in Response to Therapy for Cardiovascular Diseases
Current Pharmacogenomics and Personalized Medicine Autophagy Modulators and Neuroinflammation
Current Medicinal Chemistry Influence of Genetic Background on Apathy-Like Behavior in Triple Transgenic AD Mice
Current Alzheimer Research HIV-1 Tat-Induced Changes in Synaptically-Driven Network Activity Adapt During Prolonged Exposure
Current HIV Research Chemoinformatics Approaches for Traditional Chinese Medicine Research and Case Application in Anticancer Drug Discovery
Current Drug Discovery Technologies Small Molecule Natural Products and Alzheimer’s Disease
Current Topics in Medicinal Chemistry Up-regulation of DMN Connectivity in Mild Cognitive Impairment Via Network-based Cognitive Training
Current Alzheimer Research Characterization of the Early CNS Stress Biomarkers and Profiles Associated with Neuropsychiatric Diseases
Current Genomics A Medicinal Mushroom: Phellinus Linteus
Current Medicinal Chemistry The Retrogenesis Model in Alzheimer’s Disease: Evidence and Pract ical Applications
Current Psychiatry Reviews Focus on the Different Projects of Telemedicine Centered on the Elderly In France
Current Aging Science Acetylcholinesterase Inhibitor Donepezil Effects on Plasma β-Hydroxybutyrate Levels in the Treatment of Alzheimer’s Disease
Current Alzheimer Research Mild Cognitive Impairment: Advantages of a Comprehensive Neuropsychological Assessment
Current Alzheimer Research Sestrins: A New Kid for Stroke Treatment?
Current Drug Delivery The Pharmacological Management of Delirium in Critical Illness
Current Drug Therapy Role of Gut Microbiota in Obesity, Type 2 Diabetes and Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Spinal Microvascular Expression of PV-1 is Associated with Inflammation, Perivascular Astrocyte Loss, and Diminished EC Glucose Transport Potential in Acute SCI
Current Neurovascular Research Does Semantic Memory Impairment in Amnestic MCI with Hippocampal Atrophy Conform to a Distinctive Pattern of Progression?
Current Alzheimer Research Alzheimer's Disease and the Routine Clinical Use of CSF Biomarkers
CNS & Neurological Disorders - Drug Targets